Drug Profile
HMBD 004
Alternative Names: anti-CD47xCD33 bispecific antibody - Hummingbird Bioscience; HMBD-004Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Hummingbird Bioscience
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in Singapore (Parenteral)
- 09 Dec 2017 Preclinical trials in Haematological malignancies in Singapore (Parenteral) before December 2017
- 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)